No Data
No Data
ASX Market Update: Telcos Strong in Weak Market | 10 July 2024
The ASX is down 0.3% to 7,807 points heading into lunchtime trade.
Imugene Commences Patient Dosing in Phase 1 Bile Tract Cancer Trial; Shares Up 8%
Immuno-oncology company Imugene (ASX:IMU) said that the first patient has been dosed at St Vincent's Hospital in Melbourne, Victoria, as part of its bile tract cancer trial for VAXINIA, according to
2 ASX Shares Roaring Higher on Big News
The market may have run out of steam on Wednesday, but not all ASX shares are falling.
Imugene Doses First Patient for VAXINIA Bile Tract Cancer Trial in Melbourne
Imugene Ltd (ASX:IMU, OTC:IUGNF) has dosed the first patient in its trial for bile tract cancer (cholangiocarcinoma) patients.
Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6%
Imugene (ASX:IMU) dosed the first patient in the intravenous (IV) infusion combination arm of the phase one clinical trial for bile tract cancer, the clinical stage immuno-oncology company said in a M
Is Imugene (ASX:IMU) In A Good Position To Deliver On Growth Plans?
No Data